- 1. B Cell
- [lymphoid cells concerned with humoral immunity; they are short lived cells resembling bursa derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation. ( CSP )] (UMLS (NCI) C0004561) =Cell ;
| - 51. BC-2
- [Encoded by human BC-2 Gene, 222-amino acid 32 kD BC-2 Protein has an unknown function and low similarity to Vps24p (S. cerevisiae). (from SWISS-PROT, LocusLink, and NCI) ( NCI )] (UMLS (NCI) C1332383) BC-2 Protein;
Putative Breast Adenocarcinoma Marker Protein (32kD) =Amino Acid, Peptide, or Protein; Biologically Active Substance |
- 2. B cell acquired immunodeficiency
- [ ] (UMLS (CSP) C1328844) =Disease or Syndrome ;
| - 52. BCAA
- [Encoded by human RBBP1L1 Gene, 803-amino acid 91 kD RBP1-Like Protein is similar to RBP1, containing a Tudor domain and an ARID DNA binding domain. Different protein isoforms are thought to exist, but all have not been fully determined. Variant 2 encodes a shortened isoform 2 that lacks an internal protein fragment. (from SWISS-PROT, LocusLink, and NCI) ( NCI )] (UMLS (NCI) C1337094) BCAA Protein;
BRCAA1 Protein;
Breast Cancer-Associated Antigen BRCAA1;
Breast Carcinoma-Associated Antigen BCAA;
KIAA0117 Protein;
Rb-Binding Protein Homolog;
RBBP1L1 Protein;
RBP1-Like Protein;
Retinoblastoma-Binding Protein 1-Like 1 =Amino Acid, Peptide, or Protein; Biologically Active Substance |
- 3. B cell activating factor
- [lymphokine produced by antigen or mitogen activated T lymphocytes that enhances the ability of B lymphocytes to present antigen, primes B lymphocytes to proliferate in response to anti-Ig and lipopolysaccharide, and regulates the production of IgG and IgE by B lymphocytes; it also acts as a growth factor for T lymphocytes and as a maturation factor for mast cells. ( CSP )] (UMLS (CSP) C0021758) =Amino Acid, Peptide, or Protein; Immunologic Factor =lymphokine;
hematopoietic growth factor | - 53. BCAP
- (UMLS (NCI) C1510468) BLEO/CDDP/CTX/DOX;
Bleomycin/Cisplatin/Cyclophosphamide/Doxorubicin =Therapeutic or Preventive Procedure ;
|
- 4. B Cell Childhood Acute Lymphoblastic Leukemia
- (UMLS (NCI) C0279584) =Neoplastic Process
| - 54. BCAR1
- [This gene plays a role in signal transduction and is involved in cell adhesion, migration and proliferation. ( NCI )] (UMLS (NCI) C1366459) BCAR1 Gene;
Breast Cancer Anti-Estrogen Resistance 1 Gene =Gene or Genome ◊ [Encoded by human BCAR1 Gene, conserved ubiquitous 870-amino acid 116 kD cytoplasmic p130CAS (CAS Family) is an adaptor molecule: Ser-region, NH-SH3, central YXXP motif SH2-binding site substrate domain, SRC SH3-binding site COOH Pro-rich binding region, and C-terminal HLH. SH3 localizes CAS to focal adhesions; interacts with FAK1 P-rich region. FAK1 phosphorylates CAS YDYVHL motif. SRCs phosphorylate CAS. CAS SH2-binding sites may bind CRK, NCK, and ABL. CAS HLH may dimerize CASL. CAS Ser region promotes serum response. CAS moves to focal adhesions upon integrin triggered Y-phosphorylation. CAS complexes with CRKL and LYN. CAS functions in cardiovascular development, actin assembly, cell migration, and growth. Over expression confers breast cancer anti-estrogen resistance. (from SWISS-PROT, OMIM, and NCI) ( NCI )] (UMLS (NCI) C1451357) BCAR1 Protein; Breast Cancer Anti-Estrogen Resistance 1 Protein; CAS; CRKAS; CRK-Associated Substrate; p130CAS Amino Acid, Peptide, or Protein; Biologically Active Substance ; |
- 5. B Cell Chronic Lymphocytic Leukemia
- [A slowly progressing disease in which too many white blood cells (called lymphocytes) are found in the body. ( NCI )] (UMLS (NCI) C0023434) =Neoplastic Process ;
=Leukemia, Lymphocytic;
=Acute B Cell Lymphocytic Leukemia;
Leukemia, B-Cell, Chronic;
Leukemia, Pre-B-Cell;
| - 55. BCAR2
- [This gene is involved in tumorigenesis. ( NCI )] (UMLS (NCI) C1332385) BCAR2 Gene;
Breast Cancer Anti-Estrogen Resistance 2 Gene =Gene or Genome ;
◊ [Encoded by human BCAR2 Gene, Breast Cancer Anti-Estrogen Resistance 2 Protein is similar to gamma-butyrobetaine 2-oxoglutarate dioxygenase (C. elegans, Drosophila) and likely responsible for development of an anti-estrogen-resistant phenotype. (from Int J Cancer. 1997; 72:700, LocusLink, GeneCard, and NCI) ( NCI )] (UMLS (NCI) C1332615) BCAR2 Protein; Breast Cancer Anti-Estrogen Resistance 2 Protein; Amino Acid, Peptide, or Protein; Biologically Active Substance |
- 6. B cell differentiation factor
- [cytokine produced by antigen or mitogen activated T lymphocytes, fibroblasts and macrophages that serves as a differentiation factor for lymphocytes and stimulates immunoglobulin production by B lymphocytes; it also innitiates the cell cycle in primitive hematopoietic cells in vitro. ( CSP )] (UMLS (CSP) C0021760) =Amino Acid, Peptide, or Protein; Immunologic Factor =Cytokine;
hematopoietic growth factor | - 56. BCAR3
- [Encoded by human BCAR3 Gene, the 92.6 kD 825-amino acid BCAR3 Protein contains a putative SH2 domain, a hallmark of tyrosine kinase signaling molecules, and sequences homologous to CDC48 (Yeast). Abundant expression is seen in heart, placenta, skeletal muscle, spleen, prostate, testis, ovary, small intestine, colon, fetal kidney, and several cancer cell lines, but not in nonmalignant breast tissue. NSP2 induces anti-estrogen resistance in estrogen-dependent breast tumors. (from SWISS-PROT, OMIM, and NCI) ( NCI )] (UMLS (NCI) C1309026) Breast Cancer Anti-Estrogen Resistance 3;
Breast Cancer Anti-Estrogen Resistance 3 Protein;
Novel SH2-Containing Protein 2 =Amino Acid, Peptide, or Protein; Biologically Active Substance ◊ [This gene plays a role in cell cycle regulation and tumorigenesis. ( NCI )] (UMLS (NCI) C1332386) BCAR3 Gene; Breast Cancer Anti-Estrogen Resistance 3 Gene Gene or Genome ; |
- 7. B Cell Differentiation Factor I
- [lymphokine produced by antigen or mitogen activated T lymphocytes that acts as a differentiation factor for B lymphocytes and eosinophils and increases the production of IgA by B lymphocytes. ( CSP )] (UMLS (NCI) C0021759) =Amino Acid, Peptide, or Protein; Immunologic Factor =lymphokine;
hematopoietic growth factor | - 57. BCAS1
- [This gene plays a role in tumorigenesis. ( NCI )] (UMLS (NCI) C1332387) BCAS1 Gene;
Breast Carcinoma Amplified Sequence 1 Gene =Gene or Genome ;
|
- 8. B cell inborn immunodeficiency
- [ ] (UMLS (CSP) C1328845) =Disease or Syndrome ;
| - 58. BCAS2
- [This gene plays a role in transcriptional regulation. ( NCI )] (UMLS (NCI) C1332388) BCAS2 Gene;
Breast Carcinoma Amplified Sequence 2 Gene =Gene or Genome ;
◊ [Encoded by human BCAS2 Gene, the ubiquitous 225-amino acid DAM1 Protein contains a central putative N-glycosylation site and multiple N-terminal putative phosphorylation sites. A sequence identical to DAM1 is seen in Putative Spliceosome-Associated Protein SPF27. (from OMIM, and NCI) ( NCI )] (UMLS (NCI) C1332620) BCAS2 Protein; Breast Carcinoma Amplified Sequence 2; DAM1 Amino Acid, Peptide, or Protein; Biologically Active Substance |
- 9. B Cell Linker Protein
- [B-Cell Linker, encoded by the BLNK gene, is essential for normal B-cell development. This protein interfaces the B-cell receptor-associated SYK tyrosine kinase with PLC-gamma, the VAV guanine nucleotide exchange factor, and the GRB2 and NCK adaptor proteins. Tyrosine phosphorylation of B-Cell Linker by SYK provides docking sites for these SH2-containing effector molecules that, in turn permits the phosphorylation and/or activation of their respective signaling pathways. Thus, B-Cell Linker represents a central linker protein that bridges the B-cell receptor-associated kinases with a multitude of signaling pathways and may regulate biologic outcomes of B-cell function and development. The somatic loss of the BLNK gene and the accompanying block in pre-B-cell differentiation might be one of the primary causes of childhood pre-B ALL. (From OMIM and NCI) ( NCI )] (UMLS (NCI) C0756331) B-Cell Linker;
B-Cell Linker Protein;
BLNK;
=Amino Acid, Peptide, or Protein; Immunologic Factor | - 59. BCAS3
- [This gene plays a role in transcriptional regulation. ( NCI )] (UMLS (NCI) C1332389) BCAS3 Gene;
Breast Carcinoma Amplified Sequence 3 Gene =Gene or Genome ;
◊ [Encoded by human BCAS3 Gene, 913-amino acid 99.6 kD BCAS3 Protein has an unknown function. (from SWISS-PROT, LocusLink, and NCI) ( NCI )] (UMLS (NCI) C1332621) BCAS3 Protein; Breast Carcinoma Amplified Sequence 3; Amino Acid, Peptide, or Protein; Biologically Active Substance |
- 10. B cell lymphoma
- [any in a large group of nonHodgkin's lymphoma's characterized by malignant transformation of the B lymphocytes. ( CSP )] (UMLS (CSP) C0079731) =Neoplastic Process =Lymphoma, Non-Hodgkin;
=Acute B Cell Lymphocytic Leukemia;
Lymphoma, Small-Cell;
AIDS Lymphoma;
Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue | - 60. BCAS4
- [This gene plays a role in transcriptional regulation. ( NCI )] (UMLS (NCI) C1332390) BCAS4 Gene;
Breast Carcinoma Amplified Sequence 4 Gene =Gene or Genome ;
◊ [Encoded by human BCAS4 Gene, 211-amino acid 22.8 kD BCAS4 Protein has an unknown function but high similarity to a region of MAP4K1 and similarity to metalloendopeptidase (Drosophila). BCAS4 is expressed in brain, heart, liver, pancreas, prostate, kidney, and lung. (from SWISS-PROT, LocusLink, and NCI) ( NCI )] (UMLS (NCI) C1332622) BCAS4 Protein; Breast Carcinoma Amplified Sequence 4; Amino Acid, Peptide, or Protein; Biologically Active Substance |
- 11. B Cell Lymphoma Stage II
- [Stage II NHL means involvement of two or more lymph node regions on the same side of the diaphragm (II) or localized involvement of a single associated extralymphatic organ or site and its regional lymph nodes with or without other lymph node regions on the same side of the diaphragm (IIE). Note: The number of lymph node regions involved may be indicated by a subscript (e.g., II3). (PDQ) ( NCI )] (UMLS (NCI) C0855092) B-Cell Lymphoma Stage II;
Stage II B Cell Lymphoma;
Stage II B-Cell Lymphoma;
Stage II B-Cell Non-Hodgkin Lymphoma;
Stage II B-Cell Non-Hodgkin's Lymphoma =Neoplastic Process | - 61. BCD
- (UMLS (NCI) C0053048) =Therapeutic or Preventive Procedure ;
|
- 12. B Cell Lymphoma Stage III
- [Stage III NHL means involvement of lymph node regions on both sides of the diaphragm (III) that may also be accompanied by localized involvement of an extralymphatic organ or site (IIIE), by involvement of the spleen (IIIS), or both (IIIS+E). (PDQ) ( NCI )] (UMLS (NCI) C0855093) B-Cell Lymphoma Stage III;
Stage III B Cell Lymphoma;
Stage III B-Cell Lymphoma;
Stage III B-Cell Non-Hodgkin Lymphoma;
Stage III B-Cell Non-Hodgkin's Lymphoma =Neoplastic Process | - 62. BCDS1
- [Encoded by human BCDS1 Gene, BCDS1 Protein has an unknown function and is associated with breast cancer. (from LocusLink, OMIM, and NCI) ( NCI )] (UMLS (NCI) C1332445) BRCD1;
BRCD1 Protein;
Breast Cancer, Ductal, Suppressor-1 =Amino Acid, Peptide, or Protein; Biologically Active Substance |
- 13. B Cell Lymphoma Stage IV
- [Stage IV NHL means disseminated (multifocal) involvement of one or more extralymphatic sites with or without associated lymph node involvement or isolated extralymphatic organ involvement with distant (nonregional) nodal involvement. (PDQ) ( NCI )] (UMLS (NCI) C0855094) B-Cell Lymphoma Stage IV;
Stage IV B Cell Lymphoma;
Stage IV B-Cell Lymphoma;
Stage IV B-Cell Non-Hodgkin Lymphoma;
Stage IV B-Cell Non-Hodgkin's Lymphoma =Neoplastic Process | - 63. BCDS2
- [Inactivation of tumor suppressor BCDS2 Protein, encoded by Breast Cancer, Ductal 2 Gene, may represent a fundamental step in the pathogenesis of ductal carcinoma of the breast. (OMIM, LocusLink, and NCI) ( NCI )] (UMLS (NCI) C1332618) BRCD2;
Breast Cancer Suppressor-2;
Breast Cancer, Ductal 2 =Amino Acid, Peptide, or Protein; Biologically Active Substance |
- 14. B Cell Proliferation
- [Growth and reproduction of B-lymphocytes. ( NCI )] (UMLS (NCI) C1155008) =Cell Function
| - 64. BCG 9331
- (UMLS (NCI) C0299046) =Organic Chemical; Pharmacologic Substance ;
|
- 15. B cell receptor
- [membrane bound version of the specific antibody immunoglobulins produced by B lymphocytes; when BCR is occupied by antigen and the B cell is stimulated with interleukin 2, the B cell becomes activated to produce antibodies. ( CSP )] (UMLS (CSP) C0034789) =Amino Acid, Peptide, or Protein; Immunologic Factor; Receptor =antigen receptor;
| - 65. BCG Tice
- (UMLS (NCI) C0307852) =Bacterium ;
|
- 16. B Cell-Associated Molecule CD40
- [50 kD glycoprotein expressed on all B cells; plays an important role in B cell development and activation. ( CSP )] (UMLS (NCI) C0054959) =Amino Acid, Peptide, or Protein; Immunologic Factor; Receptor =CD antigen;
| - 66. BCG/5-FU
- (UMLS (NCI) C0280654) =Therapeutic or Preventive Procedure
|
- 17. B-Cell Activation
- [A set of events occurring in B lymphocytes following stimulation with cognate antigen. Crosslinking the B cell antigen receptor (surface immunoglobulin) leads to increased expression of MHC class II molecules, exit from the resting state (G0) into the G1 phase of the cell cycle, and in the case of a strong antigenic stimulus, proliferation. ( NCI )] (UMLS (NCI) C1155003) =Cell Function
| - 67. BCG/CTX/DOX/FT
- (UMLS (NCI) C0279358) =Therapeutic or Preventive Procedure
|
- 18. B-Cell Activation Protein BL34
- [Induced in response to several activation signals and encoded by B-cell specific immediate early human RGS1 Gene (RGS Family), 196-aa 22.5-kDa Regulator of G-Protein Signaling 1, containing 1 RGS domain, is likely involved in regulation of B-cell activation and proliferation. Potentially regulated by protein kinase(s), RGS1 inhibits signal transduction by increasing GTPase activity of G protein alpha subunits, driving them into the inactive GDP-bound form. ( NCI )] (UMLS (NCI) C1448758) Early Response Protein 1R20;
Regulator of G-Protein Signaling 1;
RGS1;
=Amino Acid, Peptide, or Protein; Biologically Active Substance ;
| - 68. BCG/CTX/IL-2
- (UMLS (NCI) C0279897) =Therapeutic or Preventive Procedure
|
- 19. B-Cell Chronic Lymphocytic Leukemia Tumor Suppressor LEU5
- [Encoded by human RFP2 Gene (TRIM Family), 407-aa 47-kDa RET Finger Protein 2, of unknown function, is localized to cytoplasmic bodies near the nucleus and contains a TRIM motif: 3 zinc-binding domains, a RING, type 1 and type 2 B-boxes, and a coiled-coil region. RFP2 may act as a tumor suppressor and may be involved in 13q14 deletion B-CLL. (NCI) ( NCI )] (UMLS (NCI) C1308524) CLL-Associated RING Finger;
Leukemia Associated Protein 5;
Putative Tumor Suppressor RFP2;
RET Finger Protein 2;
Tripartite Motif Protein 13 =Amino Acid, Peptide, or Protein; Biologically Active Substance | - 69. BCG/Dacarbazine
- (UMLS (NCI) C0338345) =Therapeutic or Preventive Procedure ;
|
- 20. B-Cell CLL Protein
- [Expressed in thymus, prostate, testis, ovary, small intestine, spleen, colon, and blood, 85-kb human BCL9 Gene at 1q21 encodes 1426-aa 150-kD nuclear B-Cell Lymphoma 9 Protein, containing an HD1 domain that interacts with the conserved PHD finger of PYGO1 and PYGO2. BCL9 (Lgs homolog, Drosophila) also binds to beta-Catenin, involved in WNT signal transduction pathway control of many fundamental developmental processes. BCL9 recruitment of PYGO to beta-Catenin may permit association with DNA-binding TCF to transcriptionally activate WNT target genes. BCL9 translocation that leaves the coding region intact is associated with B-cell acute lymphoblastic leukemia. ( NCI )] (UMLS (NCI) C0672585) =Amino Acid, Peptide, or Protein; Biologically Active Substance ;
| - 70. BCG/IL-2
- (UMLS (NCI) C0280836) =Therapeutic or Preventive Procedure
|
- 21. B-Cell CLL Protein
- [Encoded by widely expressed human BCL7A Gene, 231-aa 25-kD serine-rich BCL7A Protein has 90% sequence identity (N-terminal 51-aa) with BCL7B and BCL7C; possible members of an evolutionarily conserved family. BCL7A exhibits no recognizable motifs but shows homology with actin-binding Caldesmon. Recurrent three-way translocations of BCL7A with MYC and IGH occur in a high-grade B cell non-Hodgkin (Burkitt) lymphoma; the N-terminal BCL7A region is disrupted. ( NCI )] (UMLS (NCI) C1307696) BCL7A;
BCL7A Protein;
Lymphoma 7A Protein;
=Amino Acid, Peptide, or Protein; Biologically Active Substance | - 71. BCG/INH
- (UMLS (NCI) C0281144) =Therapeutic or Preventive Procedure
|
- 22. B-Cell CLL/Lymphoma 10
- [The gene was identified by its translocation in a case of mucosa-associated lymphoid tissue (MALT) lymphoma. The protein contains a caspase recruitment domain (CARD), and has been shown to induce apoptosis and to activate NF-kappaB. This protein is reported to interact with other CARD domain containing proteins including CARD9, 10, 11 and 14, which are thought to function as upstream regulators in NF-kappaB signaling. This protein is found to form a complex with MALT1, a protein encoded by another gene known to be translocated in MALT lymphoma. MALT1 and this protein are thought to synergize in the activation of NF-kappaB, and the deregulation of either of them may contribute to the same pathogenetic process that leads to the malignancy. (LocusLink) ( NCI )] (UMLS (NCI) C0766164) BCL10;
CARD-Containing Proapoptotic Protein;
CARD-Like Apoptotic Protein;
Caspase-Recruiting Domain-Containing Protein;
=Amino Acid, Peptide, or Protein; Biologically Active Substance ;
| - 72. BCG/Interferon alfa
- (UMLS (NCI) C0879369) =Therapeutic or Preventive Procedure ;
|
- 23. B-Cell CLL/Lymphoma 10 Gene
- [This gene is involved in the promotion of apoptosis. ( NCI )] (UMLS (NCI) C1367449) BCL10;
BCL10 Gene =Gene or Genome | - 73. BCG/MITO
- (UMLS (NCI) C0280764) =Therapeutic or Preventive Procedure
|
- 24. B-Cell CLL/lymphoma 2
- [A mitochondrial membrane protein, BCL-2 protein is responsible for blocking apoptosis in normal cells. Growth factor-stimulated phosphorylation by PKC promotes anti-apoptotic activity of BCL-2 during G2/M. BCL-2 regulates cell death by controlling mitochondrial membrane permeability. Cleavage by caspases during apoptosis yields a pro-apoptotic BCL-2 product that causes release of cytochrome C into the cytosol, promoting further caspase activity. Over expression from translocation t(14;18) of BCL-2 with the immunoglobulin gene region is involved in B-cell lymphomas. (from OMIM 151430 and NCI) ( NCI )] (UMLS (NCI) C0597712) =Amino Acid, Peptide, or Protein; Biologically Active Substance
| - 74. BCG/MOAB BEC2
- (UMLS (NCI) C0678027) =Therapeutic or Preventive Procedure ;
|
- 25. B-Cell CLL/Lymphoma 2 Gene
- [This gene is involved in apoptotic regulation. Overexpression of this gene promotes the pathogenesis of B-Cell lymphomas, due to anti-apoptotic activity. ( NCI )] (UMLS (NCI) C0376515) =Gene or Genome
| - 75. BCG/Monoclonal Antibody 105AD7 Anti-idiotype Vaccine
- (UMLS (NCI) C1134501) =Therapeutic or Preventive Procedure
|
- 26. B-Cell CLL/Lymphoma 3
- [A possible transcriptional activating factor, BCL3 is activated by phosphorylation and functions as an IKB specific for the p50 subunit of NFKB, inhibiting its translocation to the nucleus. BCL3 confers a survival advantage to T-cells, possibly by promoting the expression of genes repressed by NFKB members. Translocation t(14;19)(q32;q13.1), involving BCL3 and immunoglobulin gene regions, is associated with B-CLL. (from OMIM 109560 and NCI) ( NCI )] (UMLS (NCI) C0640485) =Amino Acid, Peptide, or Protein; Biologically Active Substance
| - 76. BCG/NY-ESO-1 Peptide Vaccine
- (UMLS (NCI) C1328047) =Therapeutic or Preventive Procedure ;
|
- 27. B-Cell CLL/Lymphoma 3 Gene
- [This gene is involved in transcriptional co-activation and signal transduction. ( NCI )] (UMLS (NCI) C0812238) BCL3;
BCL3 Gene =Gene or Genome | - 77. BCG/Polyvalent Melanoma Vaccine
- (UMLS (NCI) C0879365) =Therapeutic or Preventive Procedure ;
|
- 28. B-Cell CLL/Lymphoma 6 (Zinc Finger Protein 51) Gene
- [This gene is involved in transcriptional repression and plays a role in the modulation of B-cell responses. ( NCI )] (UMLS (NCI) C1332399) B-Cell CLL/Lymphoma-6 Gene;
BCL5;
BCL6;
BCL6 Gene;
Cys-His2 Zinc Finger Transcription Factor Gene;
LAZ3;
LAZ-3 Gene;
Lymphoma-Associated Zinc Finger Gene on Chromosome 3;
Zinc Finger Protein 51 Gene;
ZNF51;
ZNF51 Gene =Gene or Genome ;
| - 78. BCH-4556
- (UMLS (NCI) C0168829) =Nucleic Acid, Nucleoside, or Nucleotide; Pharmacologic Substance ;
|
- 29. B-Cell CLL/Lymphoma 7A Gene
- (UMLS (NCI) C1332400) BCL7A;
BCL7A Gene;
=Gene or Genome ;
| - 79. BCHE
- [This gene plays a role in acylcholine hydrolysis and the regulation of myeloid cells. ( NCI )] (UMLS (NCI) C1412756) BCHE Gene;
Butyrylcholinesterase Gene =Gene or Genome |
- 30. B-Cell CLL/Lymphoma 9 Gene
- [This gene plays a role in signal transduction and is involved in development. ( NCI )] (UMLS (NCI) C1332402) BCL9;
BCL9 Gene;
=Gene or Genome ;
| - 80. bcl 1 gene
- [The B-cell leukemia/lymphoma-1 genes, associated with various neoplasms when overexpressed. Overexpression results from the t(11;14) translocation, which is characteristic of mantle zone-derived B-cell lymphomas. The human c-bcl-1 gene is located at 11q13 on the long arm of chromosome 11. ( MSH )] (UMLS (CSP) C0525036) =Gene or Genome ;
|
- 31. B-cell CLL/Lymphoma-6
- [B-Cell Lymphoma 6 Protein is a zinc finger transcription factor containing an N-terminal POZ domain. It acts as a sequence-specific repressor of transcription and its activity is dependent upon DNA-binding and on the N-terminal region containing the POZ motif. This protein can interact with a variety of POZ-containing proteins that function as transcription corepressors. Target genes have roles in B-cell activation, B-cell differentiation, inflammation, and cell cycle control. Expression of BCL6 in some B-cells early in the antigen response may skew them toward a germinal center fate, away from a plasma cell fate. The BCL6 gene is found to be frequently translocated and hypermutated in diffuse large-cell lymphoma (DLCL), and may be involved in the pathogenesis of DLCL. (from OMIM, LocusLink and NCI) ( NCI )] (UMLS (NCI) C0248007) =Amino Acid, Peptide, or Protein; Biologically Active Substance ;
| - 81. BCL-1 Rearrangement
- (UMLS (NCI) C1317175) CCND1 Gene Rearrangement;
Clonal BCL-1 Gene Rearrangement;
Clonal CCND1 Gene Rearrangement;
Monoclonal BCL-1 Gene Rearrangement =Genetic Function; ;
|
- 32. B-Cell Deficiency
- (UMLS (NCI) C0522274) =Disease or Syndrome
| - 82. BCL-2 Binding Protein
- [Found only in the cytosol, TP53BP2 impedes cell cycle progression beyond G2/M. It enhances p53 trans-activation function and induces p21 (CDKN1A) expression. TP53BP2 contains ankyrin repeats and an SH3 domain, required for interaction with p53 and BCL2; TP53BP2 cannot bind both proteins simultaneously. (from OMIM 602143 and NCI) ( NCI )] (UMLS (NCI) C0290923) =Amino Acid, Peptide, or Protein; Biologically Active Substance ;
|
- 33. B-Cell Diffuse Large Cell Lymphoma of Mediastinum
- [A large B-cell non-Hodgkin lymphoma arising in the mediastinum. Morphologically it is characterized by a massive diffuse lymphocytic proliferation associated with compartmentalizing fibrosis. Response to intensive chemotherapy, with or without radiotherapy, is usually good. (WHO, 2001) ( NCI )] (UMLS (NCI) C0855152) B-Cell Diffuse Large Cell Lymphoma of the Mediastinum;
Mediastinal (Thymic) Large B-Cell Lymphoma;
Mediastinal B-Cell Diffuse Large Cell Lymphoma;
Primary Mediastinal Large B-Cell Lymphoma =Neoplastic Process | - 83. BCL-2 Gene Family
- [The BCL-2 Gene Family encodes proteins that contain Bcl-2 homology (BH) domains (1, 2, 3, or 4), involved in interactions among apoptotic protein factors that participate in programmed cell death. ( NCI )] (UMLS (NCI) C1332391) =Gene or Genome ;
|
- 34. B-Cell Lineage Specific Activator Protein
- [Paired Box 5, encoded by the PAX5 gene, is a member of the paired box (PAX) family of transcription factors. Paired Box 5 is expressed at early stages of B-cell differentiation. Its expression is also detected in developing CNS and testis. Paired Box 5 may not only play an important role in B-cell differentiation, but also in neural development and spermatogenesis. This gene is located in chromosome 9p13 region, which is involved in t(9;14)(p13;q32) translocations recurring in small lymphocytic lymphomas of the plasmacytoid subtype, and in derived large-cell lymphomas. This translocation brings the potent E-mu enhancer of the IgH gene into close proximity of the PAX5 promoters. Deregulation of PAX5 gene transcription may contribute to the pathogenesis of these lymphomas. (from LocusLink) ( NCI )] (UMLS (NCI) C0167636) =Amino Acid, Peptide, or Protein; Biologically Active Substance ;
| - 84. BCL1
- [Essential for control of the G1/S transition, cyclin D1 interacts with CDK4 and CDK6 to form a serine/threonine kinase holoenzyme and imparts substrate specificity to the complex. RB regulates cyclin D1 gene expression. Cyclin D1 expression may identify Barrett's esophagus patients at high risk for esophageal carcinoma; risk of progression to adenocarcinoma exhibits an odds ratio of 6.85. The BCL1 and PRAD1 oncogenes involve cyclin D1 gene translocations. (from J Natl Cancer Inst 2000. 92:1282 & 1316, SWISS-PROT P24385, OMIM 168461, and NCI) ( NCI )] (UMLS (NCI) C0174680) =Amino Acid, Peptide, or Protein; Biologically Active Substance
|
- 35. B-Cell Linker Gene
- [This gene plays a role in signal transduction and B-cell development. ( NCI )] (UMLS (NCI) C1332420) BLNK;
BLNK Gene;
=Gene or Genome | - 85. BCL2 gene/protein
- [over-production has been shown to make tumor cells strikingly more resistant to cell death induced by nearly all chemotherapeutic drugs and radiation, suggesting that it may be viewed as a multidrug- resistant gene. ( CSP )] (UMLS (CSP) C0872308) =Classification ;
=Cellular Oncogene;
|
- 36. B-Cell Lymphocytic Neoplasm
- (UMLS (NCI) C1332362) B-Cell Neoplasm;
=Neoplastic Process ;
| - 86. BCL2-Interacting Killer Gene
- [This gene is involved in the regulation of apoptosis and induces apoptotic activity. ( NCI )] (UMLS (NCI) C1332411) BIK;
BIK Gene;
=Gene or Genome ;
|
- 37. B-Cell Lymphoma Recurrent
- [The reemergence of B-cell non-Hodgkin lymphoma after a period of remission ( NCI )] (UMLS (NCI) C0855089) Recurrent B-Cell Lymphoma;
Recurrent B-Cell Non-Hodgkin Lymphoma;
Recurrent B-Cell Non-Hodgkin's Lymphoma =Neoplastic Process | - 87. BCL2-Like 1, Long Isoform
- [Like bcl-2 bcl-xL acts as a repressor of apoptosis. bcl-xL mediates the closure of the mitochondrial porin channel VDAC and thus regulates the release of cytochrome c during apoptosis. ( NCI )] (UMLS (NCI) C0288330) =Amino Acid, Peptide, or Protein; Biologically Active Substance
|
- 38. B-Cell Lymphoma Refractory
- [B-cell non-Hodgkin lymphoma that is resistant to treatment ( NCI )] (UMLS (NCI) C0855090) Refractory B-Cell Lymphoma;
Refractory B-Cell Non-Hodgkin Lymphoma;
Refractory B-Cell Non-Hodgkin's Lymphoma =Neoplastic Process | - 88. BCL2-Like 1, Short Isoform
- [bcl-xS has been shown to inhibit the ability of bcl-2 and bcl-xL to enhance the survival of cells. ( NCI )] (UMLS (NCI) C0288331) =Amino Acid, Peptide, or Protein; Biologically Active Substance
|
- 39. B-Cell Proliferation of Uncertain Malignant Potential
- (UMLS (NCI) C1332363) =Neoplastic Process ;
| - 89. BCL2/Adenovirus E1B 19kd Interacting Protein 3-Like Gene
- [This gene is involved in the regulation of apoptosis and induces cell death. ( NCI )] (UMLS (NCI) C1332435) BNIP3L;
BNIP3L Gene;
=Gene or Genome ;
|
- 40. B-Cell Small Lymphocytic Lymphoma
- [A non-Hodgkin lymphoma composed of monomorphic small, round B-lymphocytes in the lymph nodes. When the lymphoid process involves predominantly the bone marrow and the peripheral blood it is called chronic lymphocytic leukemia. (WHO, 2001) ( NCI )] (UMLS (NCI) C0855095) Diffuse Well Differentiated Lymphocytic Lymphoma;
Lymphoma, Small Lymphocytic;
SLL;
Small B-Cell Lymphocytic Lymphoma;
Small Lymphocytic Lymphoma =Neoplastic Process =Lymphoma, Small-Cell;
Lymphoma, Diffuse;
Low Grade Lymphoma;
| - 90. BCL2L1
- [A member of the bcl-2 protein family that plays a role in the regulation of APOPTOSIS. Two major isoforms of the protein exist due to ALTERNATIVE SPLICING of the BCL2L1 mRNA and are referred to as Bcl-XS and Bcl-XL. ( MSH )] (UMLS (NCI) C0219472) =Amino Acid, Peptide, or Protein; Biologically Active Substance ;
|
- 41. B-Cell Small Lymphocytic Lymphoma Refractory
- [B-cell small lymphocytic lymphoma that is resistant to treatment ( NCI )] (UMLS (NCI) C0855097) Refractory B-Cell Small Lymphocytic Lymphoma;
Refractory Small Lymphocytic Lymphoma;
=Neoplastic Process | - 91. BCL2L1
- [This gene is an apoptotic regulator that can have anti or pro apoptotic effects. ( NCI )] (UMLS (NCI) C1332397) BCL2L1 Gene;
BCL2-Like 1 Gene;
=Gene or Genome ;
|
- 42. B-Cell Small Lymphocytic Lymphoma Stage I
- [Ann Arbor Classification: Stage I: Involvement of a single lymph node region (I); or localized involvement of a single extralymphatic organ or site in the absence of any lymph node involvement (IE).- 2003 ( NCI )] (UMLS (NCI) C0855098) Small Lymphocytic Lymphoma Stage I;
Stage I B-Cell Small Lymphocytic Lymphoma;
Stage I Small Lymphocytic Lymphoma =Neoplastic Process | - 92. BCL2L11
- [This gene is involved in the regulation of apoptosis and promotes cell death. ( NCI )] (UMLS (NCI) C1337096) BCL2L11 Gene;
BCL2-like 11 (Apoptosis Facilitator) Gene;
=Gene or Genome ;
|
- 43. B-Cell Small Lymphocytic Lymphoma Stage II
- [Ann Arbor Classification: Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II); or localized involvement of a single extralymphatic organ or site in association with regional lymph node involvement with or without involvement of other lymph node regions on the same side of the diaphragm (IIE). - 2003 ( NCI )] (UMLS (NCI) C0855099) Small Lymphocytic Lymphoma Stage II;
Stage II B-Cell Small Lymphocytic Lymphoma;
Stage II Small Lymphocytic Lymphoma =Neoplastic Process | - 93. BCL2L2
- [This gene is involved in the regulation of apoptosis. Expression of BCL2L2 gene inhibits cellular apoptosis under cytotoxic conditions. ( NCI )] (UMLS (NCI) C1332398) BCL2L2 Gene;
BCL2-Like 2 Gene;
=Gene or Genome ;
|
- 44. B-Cell Small Lymphocytic Lymphoma Stage III
- [Ann Arbor Classification: Stage III: Involvement of lymph node regions on both sides of the diaphragm (III), which also may be accompanied by extralymphatic extension in association with adjacent lymph node involvement (IIIE) or by involvement of the spleen (IIIS) or both (IIIE,S). - 2003 ( NCI )] (UMLS (NCI) C0855100) Small Lymphocytic Lymphoma Stage III;
Stage III B-Cell Small Lymphocytic Lymphoma;
Stage III Small Lymphocytic Lymphoma =Neoplastic Process | - 94. BCNU/5-FU/IFN-A
- (UMLS (NCI) C0338172) =Therapeutic or Preventive Procedure
|
- 45. B-Cell Small Lymphocytic Lymphoma Stage IV
- [Ann Arbor Classification: Stage IV: Diffuse or disseminated involvement of one or more extralymphatic organs, with or without associated lymph node involvement; or isolated extralymphatic organ involvement in the absence of adjacent regional lymph node involvement, but in conjunction with disease in distant site(s); or any involvement of the liver or bone marrow or nodular involvement of the lung(s). - 2003 ( NCI )] (UMLS (NCI) C0855101) Metastatic Small Lymphocytic Lymphoma;
Small Lymphocytic Lymphoma Stage IV;
Stage IV B-Cell Small Lymphocytic Lymphoma;
Stage IV Small Lymphocytic Lymphoma;
=Neoplastic Process | - 95. BCNU/5-FU/SZC/VCR
- (UMLS (NCI) C0796340) Carmustine/Fluorouracil/Streptozocin/Vincristine;
=Therapeutic or Preventive Procedure |
- 46. B-Cell Translocation Gene 2 Protein
- [This protein is a member of the BTG/Tob family. This family has structurally related proteins that appear to have antiproliferative properties. This protein is involved in the regulation of the G1/S transition of the cell cycle. (LocusLink) ( NCI )] (UMLS (NCI) C1505113) BTG Family, Member 2;
BTG2;
BTG2 Protein;
NGF-Inducible Anti-Proliferative Protein PC3 =Amino Acid, Peptide, or Protein; Biologically Active Substance ;
| - 96. BCNU/BG
- (UMLS (NCI) C0281639) =Therapeutic or Preventive Procedure
|
- 47. B-cell/myeloid kinase
- [May serve as part of a signaling pathway coupling the FC receptor to the activation of the respiratory burst. Furthermore, it may also contribute to neutrophil migration and may regulate the degranulation process of neutrophils. p60-HCK and p59-HCK are produced by alternative initiation from the same proto-oncongene HCK. Both are expressed predominantly in cells of the myeloid and b-lymphoid lineages, thus also called B-cell/Myeloid kinase. Contains 1 sh2 domain and 1 sh3 domain. Has been mapped to chromosomal location 20q11-q12. ( NCI )] (UMLS (NCI) C0919495) Hemopoietic Cell Kinase p60;
p60-HCK;
=Amino Acid, Peptide, or Protein; Enzyme | - 97. BCNU/BLEO/MTX/PRED/VP-16
- (UMLS (NCI) C0280434) =Therapeutic or Preventive Procedure ;
|
- 48. B-CEPP
- (UMLS (NCI) C0279240) =Therapeutic or Preventive Procedure ;
| - 98. BCNU/CBDCA/TMX
- (UMLS (NCI) C0281228) =Therapeutic or Preventive Procedure ;
|
- 49. B-COMPLEX DEFIC NEC
- [ ] (UMLS (ICD9CM) C0029523) =Disease or Syndrome ;
| - 99. BCNU/CDDP
- (UMLS (NCI) C0278970) =Therapeutic or Preventive Procedure
|
- 50. BC
- [A country in Southern Africa, north of South Africa. (NCI) ( NCI )] (UMLS (NCI) C0006041) =Geographic Area
| - 100. BCNU/CDDP/CTX
- (UMLS (NCI) C0278671) =Therapeutic or Preventive Procedure
|
home
